I use a multi-scale analysis, combining pharmacology, optogenetics and animal behavior, to study how the emotional and olfactory systems interact and converge in psychiatric disorders, notably depression and bipolar disorder. The ultimate goal is to use olfaction and the olfactory system as a reliable tool in fine diagnosis, prognosis and monitoring of disease progression and, ultimately, as an effective therapeutic target for affective disorders.
The link between olfaction and emotion in bipolar disorders
Bipolar disorders (BD) is a prevalent and debilitating chornic psychiatric illness that generates a considerable cost for the society. Beyond mood episodes, manic or depressive, growing evidence has shown that BD patients even during […]
Astroglial changes during sepsis associated encephalopathy
Sepsis associated encephalopathy (SAE), a major complication of sepsis is characterized by impairment of consciousness which ranges from delirium to coma and is associated to electroencephalogram (EEG) pattern alterations, increased mortality as well as […]
When Gut Bacteria Changes Brain Functions
We are interested in deciphering the relationships that link gut microbiota with the immune system and the brain. So far, the mechanisms underlying these interplay, and most importantly their consequences, remain largely unknown. Therefore […]
OLFACTORY MEANS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MOOD DEPRESSION
The application relates to the measure of olfactory discrimination capacity in subjects affected by a psychiatric disorder or disease involving mood disturbance, more particularly mood depression. The application provides means that are especially adapted […]
2018Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner, Cell 2018 Jan;172(3):500-516.e16.
2016Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice, J. Neurosci. 2016 Jan;36(2):518-31.
2013CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice, Cereb. Cortex 2015 Jan;25(1):35-45.
2012Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice, Neuropharmacology 2013 Apr;67:183-92.
2012Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline, Neurosci. Lett. 2012 Mar;511(2):110-5.
2011Minocycline restores olfactory bulb volume and olfactory behavior after traumatic brain injury in mice, J. Neurotrauma 2012 Jan;29(2):354-61.
2011Minocycline restores sAPPα levels and reduces the late histopathological consequences of traumatic brain injury in mice, J. Neurotrauma 2011 Oct;28(10):2135-43.